摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

spiro[5.5]undec-1-en-2-yl-methanol | 1147729-05-2

中文名称
——
中文别名
——
英文名称
spiro[5.5]undec-1-en-2-yl-methanol
英文别名
Spiro[5.5]undec-1-ene-2-methanol;spiro[5.5]undec-4-en-4-ylmethanol
spiro[5.5]undec-1-en-2-yl-methanol化学式
CAS
1147729-05-2
化学式
C12H20O
mdl
——
分子量
180.29
InChiKey
YVRFAFIAEFTKLT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    297.8±9.0 °C(predicted)
  • 密度:
    0.99±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE
    申请人:OHKOUCHI Munetaka
    公开号:US20120277150A1
    公开(公告)日:2012-11-01
    [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    提供一种包含GPR40激活剂的药剂,其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、该化合物或盐的溶剂化合物等,特别是胰岛素促分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药物。解决问题的方法是使用式(I)的化合物:(其中p为0至4;j为0至2;k为0至1;环A为芳基、杂环基、环烷基、环烯基、螺环基;环B为芳基、杂芳基;X为0或-NR7-;R1至R7和L为特定基团),该化合物的盐或该化合物或盐的溶剂化合物。
  • Spiro compounds and pharmaceutical use thereof
    申请人:Japan Tobacco Inc.
    公开号:US08299296B2
    公开(公告)日:2012-10-30
    The spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof
    以下是通用式[Ia]所代表的螺环化合物,其药学上可接受的盐或其溶剂化物。
  • NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES
    申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
    公开号:US20130210721A1
    公开(公告)日:2013-08-15
    [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    [目的] 提供一种GPR40激活剂,其中包含一种具有GPR40激动剂作用的新化合物作为活性成分,该化合物的盐、化合物或盐的溶剂合物等,特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症或其他疾病的药物。 [解决问题的方法] 公式(I)的化合物: 其中p为0至4;j为0至2;k为0至1;环A为芳基、杂环基、环烷基、环烯基、螺环基;环B为芳基、杂芳基;X为O或-NR7-;R1至R7和L为特定的基团,该化合物的盐或化合物或盐的溶剂合物。
  • SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES
    申请人:Japan Tobacco Inc.
    公开号:EP2202216A1
    公开(公告)日:2010-06-30
    The spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof
    以下通式[Ia]代表的螺环化合物、其药学上可接受的盐或其溶液
  • US8299296B2
    申请人:——
    公开号:US8299296B2
    公开(公告)日:2012-10-30
查看更多